[go: up one dir, main page]

WO2007028145A3 - Agents et procede permettant de reduire l'activite de la proteine tyrosine phosphatase 1b dans le systeme nerveux central - Google Patents

Agents et procede permettant de reduire l'activite de la proteine tyrosine phosphatase 1b dans le systeme nerveux central Download PDF

Info

Publication number
WO2007028145A3
WO2007028145A3 PCT/US2006/034467 US2006034467W WO2007028145A3 WO 2007028145 A3 WO2007028145 A3 WO 2007028145A3 US 2006034467 W US2006034467 W US 2006034467W WO 2007028145 A3 WO2007028145 A3 WO 2007028145A3
Authority
WO
WIPO (PCT)
Prior art keywords
reduce
activity
nervous system
central nervous
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/034467
Other languages
English (en)
Other versions
WO2007028145A2 (fr
Inventor
Louis Herlands
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dara Biosciences Inc
Original Assignee
Dara Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dara Biosciences Inc filed Critical Dara Biosciences Inc
Publication of WO2007028145A2 publication Critical patent/WO2007028145A2/fr
Publication of WO2007028145A3 publication Critical patent/WO2007028145A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des compostions pharmaceutiques et des procédés d'administration au le système nerveux central destinés à réduire l'activité de la protéine tyrosine phosphatase 1B (PTP1B), à réduire les concentrations de glucose périphériques, à réduire la production de glucose, à réduire les taux de lipides, triglycérides et/ou cholestérol (par exemple, dans le sang, le plasma ou le sérum), et/ou l'ingestion d'aliments et/ou à traiter un trouble du métabolisme tel que le diabètes (par exemple, de type I ou type II), le syndrome métabolique, l'hyperglycémie, la résistance à l'insuline, les intolérances au glucose et/ou l'obésité et/ou à traiter des troubles, tels que la résistance à la leptine, la déficience en gonadotropine, l'insuffisance cardiaque, l'ischémie, l'athérosclérose, la coronaropathie, l'hyperlipidémie, l'hypertriglycéridémie, l'hypercholestérolémie, le déficit familial en lipoprotéine lipase, l'hypertension, l'aménorrhée, le cancer (notamment des cancers formant des tumeurs), la maladie neurodégénérative et/ou le syndrome des ovaires polykystiques. L'invention concerne également un dispositif d'administration comprenant une composition pharmaceutique selon l'invention.
PCT/US2006/034467 2005-09-02 2006-09-01 Agents et procede permettant de reduire l'activite de la proteine tyrosine phosphatase 1b dans le systeme nerveux central Ceased WO2007028145A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US71406205P 2005-09-02 2005-09-02
US60/714,062 2005-09-02
US78596506P 2006-03-24 2006-03-24
US60/785,965 2006-03-24

Publications (2)

Publication Number Publication Date
WO2007028145A2 WO2007028145A2 (fr) 2007-03-08
WO2007028145A3 true WO2007028145A3 (fr) 2007-10-11

Family

ID=37809651

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/034467 Ceased WO2007028145A2 (fr) 2005-09-02 2006-09-01 Agents et procede permettant de reduire l'activite de la proteine tyrosine phosphatase 1b dans le systeme nerveux central

Country Status (1)

Country Link
WO (1) WO2007028145A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8242092B2 (en) 2008-02-05 2012-08-14 Brent Townshend Protein tyrosine phosphatase inhibitors

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
EP2310372B1 (fr) 2008-07-09 2012-05-23 Sanofi Composés hétérocycliques, leur procédé de préparation, médicaments les contenant et leur utilisation
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
ES2443016T3 (es) 2009-08-26 2014-02-17 Sanofi Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo
JP5748154B2 (ja) 2009-12-16 2015-07-15 ニヴァリス・セラピューティクス・インコーポレーテッド Ｓ−ニトロソグルタチオンレダクターゼの新規なチオフェン系阻害薬
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
EP2582709B1 (fr) 2010-06-18 2018-01-24 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
EP2683699B1 (fr) 2011-03-08 2015-06-24 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
EP2683705B1 (fr) 2011-03-08 2015-04-22 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
EP2766349B1 (fr) 2011-03-08 2016-06-01 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
EP2683700B1 (fr) 2011-03-08 2015-02-18 Sanofi Dérivés d'oxathiazine tétra-substitués, leur procédé de fabrication, leur utilisation comme médicament ainsi que médicaments en étant pourvu et leur utilisation
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP2760862B1 (fr) 2011-09-27 2015-10-21 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
US11168093B2 (en) 2018-12-21 2021-11-09 Celgene Corporation Thienopyridine inhibitors of RIPK2

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003041729A1 (fr) * 2001-09-26 2003-05-22 Albert Einstein College Of Medicine Of Yeshiva University Inhibiteurs et ligands de ptp1b
US6602867B1 (en) * 1999-01-12 2003-08-05 Abbott Laboratories Triazole compounds with dopamine-D3-receptor affinity
US20040186124A1 (en) * 2003-01-06 2004-09-23 Wynne Graham Michael (2-carboxamido)(3-amino)thiophene compounds
US20050124656A1 (en) * 2002-01-29 2005-06-09 Applied Research Systems Ars Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps)

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602867B1 (en) * 1999-01-12 2003-08-05 Abbott Laboratories Triazole compounds with dopamine-D3-receptor affinity
WO2003041729A1 (fr) * 2001-09-26 2003-05-22 Albert Einstein College Of Medicine Of Yeshiva University Inhibiteurs et ligands de ptp1b
US20050124656A1 (en) * 2002-01-29 2005-06-09 Applied Research Systems Ars Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps)
US20040186124A1 (en) * 2003-01-06 2004-09-23 Wynne Graham Michael (2-carboxamido)(3-amino)thiophene compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GIROUX ET AL.: "Nassal Drug deposition, controlled particle dispersion: Applying vertical flow to optimize hasal drug deposition", DRUG DELIVERY TECHNOLOGY, vol. 5, no. 3, March 2005 (2005-03-01), pages 44 - 49 *
IVERSEN ET AL.: "Structure-based Design of a Low Molecular Weight, Nonphosphorus, Nonpeptide, and Highly Selective Inhibitor of Protein-tyrosine Phosphatase 1B", J. BIOL. CHEM., vol. 275, no. 14, April 2000 (2000-04-01), pages 10300 - 10307, XP002902040, DOI: doi:10.1074/jbc.275.14.10300 *
PETTI ET AL.: "Temporal quantitation of mutant kit tyrosine signaling attenuated by a novel thiophene kinase inhibitor OSI-930", MOL. CANCER, vol. 4, June 2005 (2005-06-01), pages 1188 - 1197 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8242092B2 (en) 2008-02-05 2012-08-14 Brent Townshend Protein tyrosine phosphatase inhibitors

Also Published As

Publication number Publication date
WO2007028145A2 (fr) 2007-03-08

Similar Documents

Publication Publication Date Title
WO2007028145A3 (fr) Agents et procede permettant de reduire l'activite de la proteine tyrosine phosphatase 1b dans le systeme nerveux central
BR0318046A (pt) Compostos de hidroxila e composições para controle de colesterol e empregos relacionados
Volpe et al. Cellular death, reactive oxygen species (ROS) and diabetic complications
Kuivenhoven et al. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia
Bustanji et al. Pancreatic lipase inhibition activity of trilactone terpenes of Ginkgo biloba
Siddiqui et al. Saroglitazar, a dual PPAR α/γ agonist, improves atherogenic dyslipidemia in patients with non-cirrhotic nonalcoholic fatty liver disease: a pooled analysis
Petyaev State of the art paper improvement of hepatic bioavailability as a new step for the future of statin
Wu et al. In vivo pharmacodynamic and pharmacokinetic effects of metformin mediated by the gut microbiota in rats
Kim et al. Steam-dried ginseng berry fermented with Lactobacillus plantarum controls the increase of blood glucose and body weight in type 2 obese diabetic db/db mice
Wu et al. Neohesperidin exerts lipid-regulating effects in vitro and in vivo via fibroblast growth factor 21 and AMP-activated protein kinase/sirtuin type 1/peroxisome proliferator-activated receptor gamma coactivator 1α signaling axis
WO2008078176A9 (fr) Procédés, composés et compositions permettant de traiter des troubles métaboliques et le diabète
WO2006031293A3 (fr) Methodes et compositions destinees au traitement de l'obesite, de maladies associees a l'insuline et de l'hypercholesterolemie
Cotugno et al. Clinical efficacy of bariatric surgery versus liraglutide in patients with type 2 diabetes and severe obesity: a 12-month retrospective evaluation
Hsu et al. Ankaflavin and monascin regulate endothelial adhesion molecules and endothelial NO synthase (eNOS) expression induced by tumor necrosis factor-α (TNF-α) in human umbilical vein endothelial cells (HUVECs)
Chen et al. Xanthohumol suppresses mylip/idol gene expression and modulates LDLR abundance and activity in HepG2 cells
WO2011031063A3 (fr) Composition de prévention ou de traitement de troubles métaboliques contenant l'anticorps anti-4-1bb
Lavasani et al. Study of the pharmacokinetic changes of Tramadol in diabetic rats
Pari et al. Antihyperlipidemic effect of coumarin in experimental type 2 diabetic rats
Sheik et al. Anti-hyperglycemic, anti-hyperlipidemic, and anti-inflammatory effect of the drug Guggulutiktaka ghrita on high-fat diet-induced obese rats
Shen et al. Klotho Protein: A Multifaceted Guardian of Healthy Aging and Its Therapeutic Potential
BRPI0406772A (pt) Composto, processos para preparar um éter fenìlico de aminoácido e o composto, composição farmacêutica, métodos para reduzir glicose, ácidos graxos livres, colesterol, e os nìveis de triglicerìdeo no plasma, para tratar obesidade, doenças autoimunes, inflamação, doença iimunológica, e um distúrbio associado com resistência a insulina, e, intermediário
Abdel-Magid GPR40 receptor agonists for the treatment of type 2 diabetes and related diseases
MX2022001460A (es) Metodos para el tratamiento de enfermedades y trastornos relacionados con apoc3.
EP1968561B8 (fr) Traitement de la nephropathie diabetique
US20180008671A1 (en) Prolonged anti-diabetic effect of fibroblast growth factor 1 (fgf1)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06802934

Country of ref document: EP

Kind code of ref document: A2